Zobrazeno 1 - 10 of 234 pro vyhledávání: '"Antibodies, Monoclonal/*therapeutic use"'
1
Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective
Autor: Katja C. Heinz, Damon Willems, Mickaël Hiligsmann
Publikováno v: Journal of Medical Economics, 25(1), 491-502. Routledge/Taylor & Francis Group
AIM: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by severe itching, erythema and scaling, causing pain, stigmatization and social isolation. Despite the growing availability of treatment options, unmet care needs rema
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac184111414f6849b66f8edbdb416a8
https://cris.maastrichtuniversity.nl/en/publications/08970300-7d24-4e7d-bbb8-094543cad961
Zobrazit plný text záznamu
2
Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
Autor: Cathrine Dawn Büttner Elgaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Publikováno v: Elgaard, C D B, Iversen, L & Hjuler, K F 2023, ' Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis ', Drugs in R&D, vol. 23, no. 2, pp. 155–163 . https://doi.org/10.1007/s40268-023-00422-w
BACKGROUND: Clinical trials have established the efficacy of brodalumab in treatment of psoriasis and psoriatic arthritis. Real-world evidence is needed to fully evaluate the drug.OBJECTIVE: Here we investigate drug survival and clinical effectivenes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c450f0e85a196986fbf8f4782ee1b2b
https://pure.au.dk/portal/da/publications/singlecentre-realworld-study-on-drug-survival-and-effectiveness-of-brodalumab-for-treatment-of-psoriasis-and-psoriatic-arthritis(9c38be6f-9124-4535-8491-d06e451958fe).html
Zobrazit plný text záznamu
3
The comparative effectiveness of migraine preventive drugs
Autor: Christian Lampl, Antoinette MaassenVanDenBrink, Christina I. Deligianni, Raquel Gil-Gouveia, Tanvir Jassal, Margarita Sanchez-del-Rio, Uwe Reuter, Derya Uluduz, Jan Versijpt, Dena Zeraatkar, Simona Sacco
Publikováno v: Journal of Headache and Pain, 24(1):56. Springer-Verlag Italia
Objective While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs. We conducted a systematic review an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a41a67abee22047c7bf39448d368ac92
https://doi.org/10.1186/s10194-023-01594-1
Zobrazit plný text záznamu
4
Antibodies to combat viral infections: development strategies and progress
Autor: Giuseppe Pantaleo, Bruno Correia, Craig Fenwick, Victor S. Joo, Laurent Perez
Publikováno v: Nature reviews. Drug discovery, vol. 21, no. 9, pp. 676-696
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for viral infections. This Review describes advances in antibody discovery and engineering that have led to the development of mAbs that target viruses such as sev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0616888852f017e928335ff4e46d5185
https://doi.org/10.1038/s41573-022-00495-3
Zobrazit plný text záznamu
5
Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity
Autor: Pfefferlé, Marc, Dubach, Irina L, Buzzi, Raphael M, Dürst, Elena, Schulthess-Lutz, Nadja, Baselgia, Livio, Hansen, Kerstin, Imhof, Larissa, Koernig, Sandra, Le Roy, Didier, Roger, Thierry, Humar, Rok, Schaer, Dominik J, Vallelian, Florence
Publikováno v: Journal for immunotherapy of cancer, vol. 11, no. 1, pp. e005718
BackgroundAgonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by n
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1069a3f48716c4418a15a2ff93f58635
https://serval.unil.ch/resource/serval:BIB_255273ACC947.P001/REF.pdf
Zobrazit plný text záznamu
6
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
Autor: Anders, Sandberg, Ernesto, Berenjeno-Correa, Rosa Crespo, Rodriguez, Michael, Axenhus, Sophia Schedin, Weiss, Kevin, Batenburg, Jeroen J M, Hoozemans, Lars O, Tjernberg, Wiep, Scheper
Publikováno v: Sandberg, A, Berenjeno-Correa, E, Rodriguez, R C, Axenhus, M, Weiss, S S, Batenburg, K, Hoozemans, J J M, Tjernberg, L O & Scheper, W 2022, ' Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts ', Alzheimer's Research & Therapy, vol. 14, no. 1, 196, pp. 196 . https://doi.org/10.1186/s13195-022-01141-1
Sandberg, A, Berenjeno-Correa, E, Rodriguez, R C, Axenhus, M, Weiss, S S, Batenburg, K, Hoozemans, J J M, Tjernberg, L O & Scheper, W 2022, ' Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts ', Alzheimer's Research and Therapy, vol. 14, no. 1, 196 . https://doi.org/10.1186/s13195-022-01141-1
Alzheimer's Research & Therapy, 14(1):196. BioMed Central
Alzheimer's Research and Therapy, 14(1):196. BioMed Central
Background In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research tools and their intrinsic i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4fd18ff48a690164d0a1ef6fc6389e8
http://www.scopus.com/inward/record.url?scp=85145091669&partnerID=8YFLogxK
Zobrazit plný text záznamu
7
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Autor: Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I. Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas, Raffaele Ornello, Uwe Reuter, Margarita Sanchez-del-Rio, Alexandra J. Sinclair, Gisela Terwindt, Derya Uluduz, Jan Versijpt, Christian Lampl
Publikováno v: Journal of Headache and Pain, 23(1). BMC
Sacco, S, Amin, F M, Ashina, M, Bendtsen, L, Deligianni, C I, Gil-Gouveia, R, Katsarava, Z, MaassenVanDenBrink, A, Martelletti, P, Mitsikostas, D D, Ornello, R, Reuter, U, Sanchez-del-Rio, M, Sinclair, A J, Terwindt, G, Uluduz, D, Versijpt, J & Lampl, C 2022, ' European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update ', Journal of Headache and Pain, vol. 23, 67 . https://doi.org/10.1186/s10194-022-01431-x
Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f3c8f2847d2637f385e9e10c8f21d8
http://hdl.handle.net/1887/3497503
Zobrazit plný text záznamu
8
Asistencia Farmacéutica a Pacientes Oncológicos que Utilizan Anticuerpos Monoclonales en un Hospital de Referencia en el Oeste de Santa Catarina
Autor: Leonel, Renan Martinelli, Reis, Flávia Medeiros Dutra, Andolfatto, Daniel, Oliveira, Gabriela Gonçalves de
Publikováno v: Revista Brasileira de Cancerologia; Vol. 68 No. 3 (2022): July/Aug./Sept.; e-152316
Revista Brasileira de Cancerologia; Vol. 68 Núm. 3 (2022): jul./ago./sept; e-152316
Revista Brasileira de Cancerologia; v. 68 n. 3 (2022): jul./ago./set.; e-152316
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Introduction: The use of monoclonal antibodies has been incorporated into cancer treatment protocols, once their effectiveness has been proven. This type of therapy is costly and its acquisition is still an obstacle for the patient. Objective: To des
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::e603f45d5cf30beed093856f3be625e1
https://rbc.inca.gov.br/index.php/revista/article/view/2316
Zobrazit plný text záznamu
9
Radiotheranostic Agents in Hematological Malignancies
Autor: Jo Caers, Elodie Duray, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, Mireille Dumoulin, Amelie Eriksson Karlström, Matthias D’Huyvetter
Publikováno v: Frontiers in immunology. 13
Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a bro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533bef010b49708f2989d5e7e1f0a7b6
https://pubmed.ncbi.nlm.nih.gov/35865548
Zobrazit plný text záznamu
10
Chronic and Refractory Migraine: How to Diagnose and Treat
Autor: Elsa, Parreira, Isabel, Luzeiro, José Maria, Pereira Monteiro
Publikováno v: Acta Médica Portuguesa, Vol 33, Iss 11, Pp 753-760 (2020)
Migraine is highly prevalent and carries a significant personal, social and economic burden. It is the second cause of disability (years living with disability) worldwide and the first cause under 50 years of age. Chronic migraine (occurring for more
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1c6437ba49ed567c4f76e1ac7f4c0165
https://actamedicaportuguesa.com/revista/index.php/amp/article/view/12004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje